Todd Martinez, Ph.D., is Professor of Chemistry and Photon Sciences at Stanford University in Stanford, California. He also serves as Professor of Photon Science at the SLAC National Accelerator Laboratory in Menlo Park, California. Todd’s research is focused on designing molecular systems with desired functions from first principles by developing novel simulation methods to bridge…
James Rush, Ph.D. is currently Chief Executive Officer of Spica Therapeutics, a seed-stage biotech company based in Belgium that is focused on targeting macrophage subsets in different therapeutic areas. James is an expert translational immunologist and drug developer. His experience spans big pharma, biotech and startups. James has held multiple senior roles in pharma and…
H. Martin Seidel, Ph.D. has been Chief Executive Officer at IFM Therapeutics since 2019. He first joined IFM as Executive Vice President of Research and Development in 2017. IFM has achieved three successful exits with realized proceeds of $750M and more than $4B in success-based milestones based on $58M in invested capital across its IFM…
Peter Tummino, Ph.D. is President, Research and Development at Nimbus Therapeutics, where he leads the discovery, nonclinical and clinical groups. Since joining Nimbus as Chief Scientific Officer in 2019, he has been part of the leadership team. In his time at Nimbus, the company has successfully progressed the TYK2 inhibitor NDI-4858 through Phase 2 trials…
Harald Wajant is a Professor in the Department of Internal Medicine II at the University Hospital of Würzburg and Head of the Division of Molecular Internal Medicine. He graduated from the Institute of Botany at the University of Stuttgart, Germany in 1993 and was then a postdoctoral research fellow and group leader at the Institute…